Raman spectroscopy for detection of imatinib in plasma: A proof of concept

Imatinib is the standard first line treatment for chronic myeloid leukemia (CML). Owing to dose-related toxicities of Imatinib such as neutropenia, there is scope for treatment optimization through therapeutic drug monitoring (TDM). Trough concentration of 1 μg/mL is considered the therapeutic thres...

Full description

Saved in:
Bibliographic Details
Published in:Journal of innovative optical health science 2015-09, Vol.8 (5), p.1550019-1550019-11
Main Authors: Rath, Sanhita, Sahu, Aditi, Gota, Vikram, Martínez-Torres, P. G., Pichardo-Molina, J. L., Murali Krishna, C.
Format: Article
Language:English
Subjects:
chronic myeloid leukemia
DCDR
Imatinib
Raman spectroscopy
SERS
Therapeutic drug monitoring
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imatinib is the standard first line treatment for chronic myeloid leukemia (CML). Owing to dose-related toxicities of Imatinib such as neutropenia, there is scope for treatment optimization through therapeutic drug monitoring (TDM). Trough concentration of 1 μg/mL is considered the therapeutic threshhold. Existing methods for the detection of Imatinib in plasma are limited by long read out time and expensive instrumentation. Hence, Raman spectroscopy was explored as a rapid and objective tool for monitoring Imatinib concentration. Three approaches: conventional Raman spectroscopy (CRS), Drop coating deposition Raman (DCDR) spectroscopy and surface-enhanced Raman spectroscopy (SERS) were employed to detect the required trough concentration of 1 μg/mL and above. Detection of therapeutically relevant concentrations (1 μg/mL) using SERS and suitable nanoparticle substrates has been demonstrated. Prospectively, rigorous validation using clinical samples is necessary to confirm the utility of this approach in routine clinical usage.
ISSN:1793-5458
1793-7205
DOI:10.1142/S1793545815500194